GE HealthCare Raises Quarterly Dividend 14% to $0.04 Per Share

The Board of Directors of GE HealthCare Technologies Inc. (GEHC ) declared a cash dividend of $0.04 per share of common stock for the third quarter of 2026, an increase of 14% from the previous quarter, the company announced on September 22, 2026. The dividend will be payable on November 13, 2026, to all shareholders of record as of October 23, 2026.

On June 30, 2026, the board declared a cash dividend of $0.035 per share of common stock for the second quarter of 2026, payable on August 14, 2026, to shareholders of record as of July 24, 2026. The company’s second-quarter earnings release likewise recorded the declared quarterly dividend of $0.035 per share to stockholders of record as of July 24, 2026.

GE HealthCare’s condensed consolidated cash flow statement shows dividends paid to stockholders of $32 million for the six months ended June 30, 2026, the same amount paid in the six months ended June 30, 2025.

Capital Deployment and Liquidity

The dividend increase follows a second quarter in which GE HealthCare repurchased 3.3 million shares for total consideration of $200 million, according to the company’s second-quarter 2026 financial results release. The company reported $500 million remaining in the share repurchase program authorized by the Board of Directors in April 2025.

GE HealthCare reported cash and cash equivalents of $2.1 billion, access to $3.5 billion of revolving credit facilities, and total debt outstanding of $10.1 billion as of the second quarter. Second-quarter cash flow from operating activities was $168 million, up $74 million year over year, and free cash flow was $68 million, up $61 million; the company said operating cash flow included a tariff refund of $107 million. Capital expenditures were $100 million in the quarter compared with $87 million in the prior-year period, and the company said it continues to prioritize investment in capacity expansion and innovation.

Second-Quarter Results and Reaffirmed Guidance

For the quarter ended June 30, 2026, GE HealthCare reported revenues of $5.295 billion, up 5.7% year over year, including organic revenue growth of 3.5%. The company reported record organic orders growth of 11.1%, a book-to-bill of 1.15 times, and backlog of $23.9 billion. It defines book-to-bill as total orders divided by total revenues within a given financial period.

Net income attributable to GE HealthCare was $561 million versus $486 million a year earlier, and Adjusted EBIT was $750 million versus $729 million. The company said current-period measures benefited from International Emergency Economic Powers Act (IEEPA) tariff refunds recognized of $129 million for net income and $23 million for Adjusted EBIT, with tariff refunds of $106 million related to 2025 excluded from Adjusted EBIT results. Diluted earnings per share of $1.24 grew 16.5% and Adjusted EPS of $1.13 grew 6.6%, with the company stating both measures benefited from tariff refunds as well as a lower tax rate.

In the second quarter of 2026, GE HealthCare combined its Imaging and Advanced Visualization Solutions businesses into a new operating and reportable segment, Advanced Imaging Solutions, leaving three reportable segments: Advanced Imaging Solutions, Pharmaceutical Diagnostics, and Patient Care Solutions. Segment revenue for the quarter was $3,771 million for Advanced Imaging Solutions, up 7.9% year over year; $843 million for Pharmaceutical Diagnostics, up 15.6%; and $675 million for Patient Care Solutions, down 13.3%.

President and CEO Peter Arduini said the company delivered record orders and backlog in the second quarter, with orders growth across every segment. “In Patient Care Solutions, while we are focused on returning the business to growth and profitability, we are reviewing strategic options to maximize its long-term value,” Arduini said in the July 29, 2026 earnings release.

For full-year 2026, the company reaffirmed guidance of organic revenue growth of 3.0% to 4.0% year over year, Adjusted EBIT margin of 15.4% to 15.7%, an adjusted effective tax rate in the range of 20.0% to 21.0%, Adjusted EPS in the range of $4.80 to $5.00, representing 4.6% to 9.0% growth year over year, and free cash flow of approximately $1.6 billion. The company said the benefits of refunds for tariffs incurred in 2025, $106 million to date for Adjusted EBIT margin and $0.18 to date for Adjusted EPS, are not included in that guidance.